Contrasting BioLargo (NASDAQ:BLGO) and Kuraray (OTCMKTS:KURRY)

BioLargo (NASDAQ:BLGOGet Free Report) and Kuraray (OTCMKTS:KURRYGet Free Report) are both construction companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioLargo and Kuraray, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLargo 0 0 0 0 N/A
Kuraray 0 0 0 0 N/A

Risk & Volatility

BioLargo has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, Kuraray has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

Earnings and Valuation

This table compares BioLargo and Kuraray”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLargo $12.23 million 5.93 -$3.50 million ($0.03) -8.13
Kuraray $5.57 billion 0.90 $301.36 million $3.46 13.01

Kuraray has higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than Kuraray, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioLargo and Kuraray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLargo -16.53% -58.35% -32.12%
Kuraray 6.33% 6.89% 4.13%

Insider & Institutional Ownership

0.0% of BioLargo shares are owned by institutional investors. 20.3% of BioLargo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Kuraray beats BioLargo on 8 of the 11 factors compared between the two stocks.

About BioLargo

(Get Free Report)

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

About Kuraray

(Get Free Report)

Kuraray Co., Ltd. engages in the production and sale of resins, chemicals, fibers, activated carbon, and high-performance membranes and systems worldwide. The Vinyl Acetate segment manufactures and markets functional resins and films, including PVA, PVB and EVAL. The Isoprene segment engages in the manufacture and marketing of SEPTON thermoplastic elastomer, isoprene-related products, and GENESTAR. The Functional Materials segment manufactures and markets methacrylic resin, medical products, and carbon materials. The Fibers and Textiles segment manufactures and sells synthetic fibers and textiles, CLARINO manmade leather, non-woven fabrics, and other products. The Trading segment mainly processes and sells synthetic fibers and manmade leathers. It is also involved in the engineering business; design and construction of various plants; outsourcing of logistics services; temporary staffing/introduction business; design, manufacture, construction, and sale of water treatment equipment; travel and insurance agency business; golf course management; management of accommodation facilities and restaurants; manufacture and sale of hook-and loop fasteners and related products; manufacture and sale of dental materials; warehousing and logistics; and manufacturing and sales of methacrylic resin sheets, as well as provides consulting services. The company was incorporated in 1926 and is headquartered in Tokyo, Japan.

Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.